Technical Trend Overview
The stock, currently priced at ₹333.00, has shown a mixed technical profile across multiple timeframes. Weekly and monthly MACD readings remain bearish and mildly bearish respectively, indicating that momentum on a broader scale is still under pressure. However, the weekly Relative Strength Index (RSI) has turned bullish, suggesting short-term buying interest and potential for a near-term rebound. The daily moving averages also support a mildly bullish outlook, reflecting recent price gains above key short-term averages.
Bollinger Bands on both weekly and monthly charts remain mildly bearish, signalling that volatility is contained but the price is yet to break decisively higher. The KST (Know Sure Thing) indicator aligns with the MACD, showing bearish momentum on the weekly scale and mild bearishness monthly. Dow Theory and On-Balance Volume (OBV) indicators show no clear trend, underscoring the sideways consolidation phase the stock is currently undergoing.
Price Action and Volatility
On 10 Feb 2026, Gujarat Themis Biosyn Ltd recorded a high of ₹341.00 and a low of ₹324.90, closing at ₹333.00, up 2.51% from the previous close of ₹324.85. This intraday volatility reflects active trading interest, yet the stock remains well below its 52-week high of ₹479.45, indicating significant room for recovery. The 52-week low stands at ₹192.35, highlighting the stock’s wide trading range over the past year.
Despite the recent uptick, the stock’s one-month return is negative at -14.40%, contrasting with the Sensex’s modest 0.59% gain over the same period. Year-to-date performance is also weak, with a -24.74% return versus the Sensex’s -1.36%. However, the longer-term returns paint a more favourable picture, with a 15.48% gain over one year and an impressive 309.20% over three years, significantly outperforming the Sensex’s 7.97% and 38.25% respectively. Over five and ten years, the stock’s returns of 937.73% and 4341.42% dwarf the Sensex’s 63.78% and 249.97%, underscoring its strong historical growth trajectory.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
MarketsMOJO Rating and Technical Grade Changes
MarketsMOJO recently downgraded Gujarat Themis Biosyn Ltd from a Hold to a Sell rating on 21 Jan 2026, reflecting a deterioration in the company’s mojo score to 48.0. This score places the stock in the Sell category, signalling caution for investors. The market capitalisation grade remains low at 3, indicating limited size and liquidity compared to larger peers in the Pharmaceuticals & Biotechnology sector.
The downgrade is consistent with the mixed technical signals observed. While short-term indicators such as the daily moving averages and weekly RSI show mild bullishness, the dominant weekly and monthly MACD and KST readings suggest that the stock is still grappling with downward momentum. The sideways technical trend indicates a period of consolidation where neither bulls nor bears have definitive control.
Sector and Industry Context
Operating within the Pharmaceuticals & Biotechnology sector, Gujarat Themis Biosyn Ltd faces sector-wide challenges including regulatory scrutiny, pricing pressures, and competitive innovation. The sector has seen varied performance, with some companies benefiting from increased healthcare spending and others impacted by patent cliffs and supply chain disruptions.
Against this backdrop, Gujarat Themis Biosyn’s technical indicators suggest that while the stock has potential for recovery, investors should remain vigilant. The absence of clear volume trends as indicated by the neutral OBV readings further emphasises the need for confirmation of any breakout or breakdown before committing to a position.
Key Technical Indicators in Detail
MACD (Moving Average Convergence Divergence): The weekly MACD remains bearish, signalling that the short-term momentum is weaker than the longer-term trend. The monthly MACD is mildly bearish, indicating that the broader trend is still under pressure but not decisively negative. This divergence between timeframes suggests a potential for volatility and trend shifts in the near future.
RSI (Relative Strength Index): The weekly RSI has turned bullish, currently above the 50 mark, which typically indicates strengthening buying momentum. However, the monthly RSI shows no clear signal, reflecting indecision over the longer term. This mixed RSI profile supports the sideways trend classification.
Bollinger Bands: Both weekly and monthly Bollinger Bands are mildly bearish, with the price hovering near the lower band on the weekly chart. This positioning suggests that the stock is trading near oversold levels in the short term but has yet to establish a sustained upward breakout.
Moving Averages: Daily moving averages have turned mildly bullish as the stock price has crossed above key short-term averages such as the 20-day and 50-day moving averages. This is a positive sign for short-term traders looking for momentum plays.
KST (Know Sure Thing): The weekly KST remains bearish, reinforcing the MACD’s negative momentum signal. The monthly KST is mildly bearish, indicating that the stock’s momentum is still subdued on a longer timeframe.
Dow Theory and OBV: Both weekly and monthly Dow Theory assessments show no clear trend, highlighting the sideways consolidation phase. Similarly, OBV readings do not indicate significant accumulation or distribution, suggesting that volume is not confirming any directional bias.
Holding Gujarat Themis Biosyn Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaway and Outlook
Gujarat Themis Biosyn Ltd’s technical landscape is currently characterised by a cautious equilibrium. The recent price momentum shift from mildly bearish to sideways suggests that the stock is in a consolidation phase, awaiting a catalyst to break decisively in either direction. Short-term bullish signals from the RSI and daily moving averages offer some optimism, but the prevailing bearish MACD and KST readings on weekly and monthly charts counsel prudence.
Investors should closely monitor key technical levels, particularly the resistance near the recent intraday high of ₹341.00 and support around the ₹325.00 mark. A sustained move above resistance with volume confirmation could signal a resumption of upward momentum, while a breakdown below support may reinforce the bearish trend.
Given the downgrade to a Sell rating by MarketsMOJO and the modest market cap grade, the stock may be better suited for risk-tolerant investors with a long-term horizon who can withstand near-term volatility. The company’s impressive long-term returns relative to the Sensex highlight its growth potential, but the current technical signals advise caution in the short to medium term.
Overall, Gujarat Themis Biosyn Ltd remains a stock to watch closely, with technical indicators suggesting a period of indecision that could resolve into a meaningful trend shift in the coming weeks.
Unlock special upgrade rates for a limited period. Start Saving Now →
